Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.
about
Malignant Transformation in Glioma Steered by an Angiogenic Switch: Defining a Role for Bone Marrow-Derived CellsEvading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsAngiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Apatinib for molecular targeted therapy in tumorAnti-angiogenic alternatives to VEGF blockadeMonitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studiesDepot-Based Delivery Systems for Pro-Angiogenic Peptides: A ReviewCompensatory angiogenesis and tumor refractorinessEscaping Antiangiogenic Therapy: Strategies Employed by Cancer CellsTransient receptor potential canonical 4 and 5 proteins as targets in cancer therapeuticsCurrent Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/AngiogenesisMechanisms of vascularization in murine models of primary and metastatic tumor growthThe ever-expanding role of HIF in tumour and stromal biologyAdaptation to antiangiogenic therapy in neurological tumorsMulti-scale mathematical modelling of tumour growth and microenvironments in anti-angiogenic therapyIncreased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motilityIn Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening CandidatesEvaluation of Tc-99m-3PRGD2 Integrin Receptor Imaging in the Differential Diagnosis of Breast Lesions and Comparison With Mammography.High-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation.Damage effect of high-intensity focused ultrasound on breast cancer tissues and their vascularities.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis.Monitoring the vascular response and resistance to sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI.Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancerDIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system.A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth.Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I studyImmunohistochemical analysis of the mechanistic target of rapamycin and hypoxia signalling pathways in basal cell carcinoma and trichoepithelioma.Soy and breast cancer: focus on angiogenesis.Host deficiency in caveolin-2 inhibits lung carcinoma tumor growth by impairing tumor angiogenesis.Anti-angiogenic therapies for advanced esophago-gastric cancerTargeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2.Role of caveolin-2 in subcutaneous tumor growth and angiogenesis associated with syngeneic mouse Lewis lung carcinoma and B16 melanoma modelsIdentification of novel vascular targets in lung cancer.A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivSmall-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.Angiogenesis dependent characteristics of tumor observed on rabbit VX2 hepatic carcinoma.Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data.Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
P2860
Q26765887-8129579F-1643-4C9D-A771-1BF4D75D547DQ26773795-92C6B0C4-0840-4DA3-A773-14EF901CBD94Q26775394-B9F07A74-C352-4F8E-ACD9-E06F956F3E2BQ26775828-B99C1788-EEB5-4912-8251-540E2BD225FEQ26775947-2C59EE7E-33B6-4CEA-BCE7-7034BA771144Q26778463-CF1EE429-0C6F-4674-99D9-597016506026Q26799856-71DC7D4C-5FF0-45BD-9EA0-6444E217838AQ26851916-A96604CE-4282-4995-B4A1-71997A2195A6Q28067753-CB30A454-00B5-4BE2-AB27-926D9F295C81Q28073760-2AEE9EB6-109A-4A9F-8C52-E5B186508973Q28077780-8C2CCA04-7327-4395-9C68-9E3D2917E1CDQ28077790-B26ED77E-24AD-4446-BC0D-4F1F7CE12D95Q28079015-D10079D0-A4E5-4C2F-ADAB-25395A83BA74Q28082908-CE4D3F29-C2DC-4A26-A713-428353A81E65Q28818449-99B6D982-6D59-447C-A11F-F4E5CC96AFE0Q28820722-114DC53F-3EAA-4F60-98F1-79EF3FA3E593Q28820755-4E8A1DB4-8E07-41EC-B681-397B3CF49F4DQ30274889-2CA0A5AC-E8CA-4C61-8B7B-36BCF4EDB0CEQ30365660-0DD958DC-0622-4D2B-9BAD-E57BD874B03EQ30382852-1DFAC4F6-CE63-4333-B6E4-3DCE92F90EB3Q30399006-5806C345-6D21-4E37-888C-BABD908A4039Q30839218-09ADC436-2E54-4692-A231-C85BA81AD1FAQ32176092-1A933276-0251-4DB3-AB8A-846B784B49FFQ33434465-A16A41C6-CB3B-4E8D-8B52-3A17B7A50170Q33787360-8B2B4C2F-A4E4-48DE-9C54-D081CBADC4ECQ33869764-5A103DCB-9E82-4EDA-89BB-F7E7F46F45D7Q33877489-4FDBC47A-2321-49F0-B9DC-C0C324132213Q33885479-128CBB23-2779-4DA8-97D9-90C1D0AFEAE7Q34122334-45629DFF-B50E-4B57-AFFF-48D0E83BE01CQ34477740-65ABA1C8-3CB9-4CC8-B04A-0BCA6A25A4ACQ34518452-28D6581D-C631-405E-89C3-C29F650688EDQ34686222-E65606DA-048E-4755-B418-18249C3BB438Q35126158-26C88EB1-6836-41CF-B48F-F1B918CF0078Q35636901-117725B9-120B-4545-A192-63E2F11042C4Q35677838-C3CFBD8D-CB3E-4C6A-A7E0-06D806C1345FQ35695946-EBFFBDF7-B4E7-4F1A-A2B7-5CD1715EE728Q35743521-CE800B0C-06D8-40F6-9C1D-BFB5961B1CF5Q35882982-9ED1B22A-6C4C-466E-BFF0-FEF47325D7E1Q35966871-EB89B25B-4F9D-4A0E-920A-B6B1E6E70D3BQ35983858-8D286F9B-F97F-49C1-B72F-0A91982B3BDE
P2860
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Anti-angiogenic therapy for ca ...... estions and future directions.
@ast
Anti-angiogenic therapy for ca ...... estions and future directions.
@en
type
label
Anti-angiogenic therapy for ca ...... estions and future directions.
@ast
Anti-angiogenic therapy for ca ...... estions and future directions.
@en
prefLabel
Anti-angiogenic therapy for ca ...... estions and future directions.
@ast
Anti-angiogenic therapy for ca ...... estions and future directions.
@en
P2860
P1154
2-s2.0-84957942518
P1433
P1476
Anti-angiogenic therapy for ca ...... estions and future directions.
@en
P2093
Andrew R Reynolds
Naveen S Vasudev
P2860
P2888
P304
P356
10.1007/S10456-014-9420-Y
P5530
P577
2014-01-31T00:00:00Z
2014-07-01T00:00:00Z
P5875
P6179
1002496314